1st May 2015 07:35
LONDON (Alliance News) - Vernalis PLC on Friday said the US Food and Drug Administration has approved the new drug application made for the Tuzistra XR extended release oral suspension.
The product, which was developed by Vernalis using the LiquiXR technology made by partner Tris Pharma Inc, is an extended-release oral suspension combination of codeine and chlorpheniramine to be used for treating coughs and symptoms associated with the common cold.
"The approval of Tuzistra XR is a very significant moment in the evolution of Vernalis to a commercial stage speciality pharmaceutical company. We believe this product offers both patients and physicians an extended relief alternative to existing treatments and presents a significant commercial opportunity for Vernalis," said Vernalis Chief Executive Ian Garland.
Shares in Vernalis were up 14% to 58.47 pence in early trade, one of the best performers in the AIM All-Share.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Vernalis PLC